Novartis & Cell Therapies announcement

We’re excited to announce the approval by the Therapeutic Goods Administration of our chimeric antigen receptor T cell (CAR-T) one-time therapy to be manufactured here in Australia at the Cell Therapies facility, based out of the The Peter MacCallum Cancer Centre in Melbourne.

To find out more watch here:

To read more about the announcement click here